# Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients

> **NCT00294866** · PHASE4 · COMPLETED · sponsor: **Fresenius Medical Care North America** · enrollment: 64 (actual)

## Conditions studied

- Kidney Failure

## Interventions

- **DRUG:** Paricalcitol

## Key facts

- **NCT ID:** NCT00294866
- **Lead sponsor:** Fresenius Medical Care North America
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2010-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00294866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00294866, "Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00294866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*